Shanghai RAAS: Application for new clinical trial indications for SR604 injection has been accepted
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, Shanghai RAAS announced that the company recently received the "Acceptance Notice" issued by the National Medical Products Administration, agreeing to accept the company's application for clinical trials of the new indication "prevention and treatment of bleeding episodes in patients with vascular hemophilia" for SR604 injection. SR604 injection is a humanized high-affinity monoclonal antibody preparation that specifically inhibits the anticoagulant function of human activated protein C
According to the Zhitong Finance APP, Shanghai RAAS (002252.SZ) announced that the company recently received the "Acceptance Notice" issued by the National Medical Products Administration, agreeing to accept the company's application for clinical trials of the new indication "prevention and treatment of bleeding episodes in patients with vascular hemophilia" for the SR604 injection. The SR604 injection is a humanized high-affinity monoclonal antibody preparation that specifically inhibits the anticoagulant function of human activated protein C